rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    GKOS
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Glaukos (GKOS) Stock Fair Value Rises After Analysts Lift Targets On Strong Q3
      Nov 14Yahoo FinanceGKOS
      Could You Have Held Glaukos Stock Through Its Falls?
      Nov 14Yahoo FinanceGKOS
      What Supports Glaukos Corporation (GKOS) for a Powerful Profit Cycle?
      Nov 12Yahoo FinanceGKOS
      What iShares Russell 2000 (IWM) Sold: Glaukos Leads on Nov. 10
      Nov 12Yahoo FinanceGKOSIWM
      What iShares Russell 2000 Index Fund (IWM) Bought: Glaukos Leads on Nov. 9
      Nov 11Yahoo FinanceGKOS
      What iShares Russell 2000 Index Fund (IWM) Sold: Glaukos Leads on Nov. 6
      Nov 10Yahoo FinanceGKOSIWDIWMIWV
      Did Raised Sales Guidance Just Shift Glaukos (GKOS) Investment Narrative?
      Nov 8Yahoo FinanceGKOS
      SPDR S&P MidCap 400 ETF (MDY) Adds Glaukos and United Therapeutics on Wednesday
      Nov 6Yahoo FinanceUTHRGKOSMDYMDYGSPMD
      What iShares Russell 2000 Index Fund (IWM) Bought: Glaukos Leads on Wednesday
      Nov 6Yahoo FinanceGKOSIWDIWM
      iShares Core S&P Mid-Cap (IJH) Adds Glaukos and TechnipFMC on Nov. 3
      Nov 5Yahoo FinanceFTIGKOSIJHIVVSPMD
      ETFs Bought $385.0 Million of Glaukos (GKOS) on Tuesday
      Nov 5Yahoo FinanceGKOS
      Is Glaukos (GKOS) Still Cheap After Record Sales And Profit?

      Glaukos has turned into one of the market’s stronger healthcare stories in 2026, with the share price climbing sharply as investors respond to record sales, index moves and a shift into profitability. With the stock now at US$233.04, the real question for you is whether that price still lines up with the cash flows the business is expected to generate, based on a Discounted Cash Flow (DCF) view of intrinsic value. Glaukos has returned 347.6% over the past 5 years, which puts real weight on...

      Nov 4Yahoo FinanceGKOS
      Glaukos CDO Tomas Navratil sells $10.6 million in company shares
      Nov 4Investing.comGKOS
      Glaukos (GKOS) Joins The S&P 400, Is It Overvalued At Current Levels?
      Nov 4Yahoo FinanceGKOS
      Glaukos Announces Participation in Upcoming Investor Conferences
      Nov 3Yahoo FinanceGKOS
      iShares Russell 2000 (IWM) Adds Jackson Financial, Trims Glaukos on Thursday
      Nov 2Yahoo FinanceGKOSJXNIWDIWFIWMIWO
      H.C. Wainwright raises Glaukos stock price target on strong results
      Oct 30Investing.comGKOS
      Glaukos (GKOS) Earnings, Outlook ‘Brighter’; Shares Soar to All-Time High
      Oct 30Yahoo FinanceGKOS
      Glaukos (GKOS) Stock Charges Higher On Q3 Earnings Surprise
      Oct 30Yahoo FinanceGKOS
      Glaukos Sets $1 Billion 2027 Sales Goal: Rapid Earnings Reaction
      Oct 29Yahoo FinanceGKOS
      Glaukos Shares Rise After Q3 Beat, Guidance Raised
      Oct 29Yahoo FinanceGKOS
      12 Health Care Stocks Moving In Thursday's Intraday Session
      Oct 29BenzingaBHCGKOSTDOC
      Why Glaukos Stock Is Surging 30% and Headed for Record Close After Earnings
      Oct 29Barron'sGKOS
      Piper Sandler raises Glaukos stock price target on Epioxa strength
      Oct 29Investing.comGKOS
      Glaukos Soars 26% on “Exceptional” Quarter and $1 Billion 2027 Sales Outlook
      Oct 29Yahoo FinanceGKOS
      Glaukos Analysts Boost Their Forecasts Following Better-Than-Expected Q3 Earnings
      Oct 29BenzingaGKOS
      Glaukos Corporation Q3 2026 Earnings Call Summary
      Oct 29Yahoo FinanceGKOS
      Needham raises Glaukos stock price target on Epioxa strength
      Oct 29Investing.comGKOS
      Glaukos stock price target raised to $225 by Mizuho on Epioxa sales
      Oct 29Investing.comGKOS
      Why Glaukos Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket
      Oct 29BenzingaGKOS
      Glaukos (GKOS) Stock Jumps 17% After Hours: What's Going On?
      Oct 29BenzingaGKOS
      Glaukos Corp (GKOS) (Q3 2026) Earnings Call Highlights: Record $211 Million in Net Sales and ...
      Oct 29Yahoo FinanceGKOS
      Glaukos (GKOS) Q3 2026 Earnings Call Transcript

      Motley Fool Press Release.

      Oct 29The Globe and MailGKOS
      Glaukos soars 13% on earnings beat and raised guidance
      Oct 29Investing.comGKOS
      Glaukos (GKOS) Q3 Earnings and Revenues Surpass Estimates
      Oct 28Yahoo FinanceGKOS
      Compared to Estimates, Glaukos (GKOS) Q3 Earnings: A Look at Key Metrics
      Oct 28Yahoo FinanceGKOS
      Earnings call transcript: Glaukos Q3 2026 beats estimates, shares jump 20%
      Oct 28Investing.comGKOS
      Glaukos: Q3 Earnings Snapshot
      Oct 28Yahoo FinanceGKOS
      Glaukos Corp earnings beat by $0.57, revenue topped estimates
      Oct 28Investing.comGKOS
      Glaukos Announces Third Quarter 2026 Financial Results
      Oct 28Yahoo FinanceGKOS
      What Glaukos Doubters Missed
      Oct 24Yahoo FinanceGKOS
      How Investors May Respond To Glaukos (GKOS) Positive Trial Results
      Oct 23Yahoo FinanceGKOS
      Stifel reiterates Glaukos stock rating on strong iDose growth
      Oct 16Investing.comGKOS
      Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally?
      Oct 14Yahoo FinanceGKOS
      Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Glaukos (GKOS)

      Detailed price information for Abbvie Inc (ABBV-N) from The Globe and Mail including charting and trades.

      Oct 13The Globe and MailGKOS
      Glaukos: Steep Premium For New Therapies And Growth (NYSE:GKOS)
      Oct 11Seeking AlphaGKOS
      Glaukos Stock: The Second J-Code Rewrites The Risk Math (NYSE:GKOS)
      Oct 10Seeking AlphaGKOS
      Glaukos Reveals Superior Intraocular Pressure Reduction With Novel Eye Therapy - Glaukos (NYSE:GKOS)

      Glaukos reports positive Phase 4 results for its iDose TR therapy, demonstrating superior efficacy over standalone cataract surgery.

      Oct 9BenzingaGKOS
      Glaukos' iDose TR meets primary goal in phase 4 trial

      Glaukos’ iDose TR Phase 4 data shows greater IOP reduction with cataract surgery vs. surgery alone. Read more here.

      Oct 9Seeking AlphaGKOS
      Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal

      GKOS expands its retinal pipeline with a licensing deal for RO-104 and exclusive RevMod platform rights, even as shares decline 6.3% following the news.

      Oct 9Yahoo FinanceGKOS

      This is the newest page. Registered accounts read further back.